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 complement system and do not provide 
a specifi c molecular diagnosis. Most of 
the genetic and molecular tests are not 
yet available for disease characterization 
in clinical laboratories. Referral to 
research laboratories is encouraged. 
However, regulatory concern, access, 
cost, and lengthy turnaround times ham-
per the role that research laboratories 
will play in clinical practice. 
With the defects of aHUS being charac-
terized in an increasing number of cases 
at the genetic and molecular levels, clini-
cians face a mounting challenge of deciding 
how to apply the vast albeit incomplete 
knowledge to the management of indi-
vidual patients.  In this regard, measures to 
block complement activation with inhibi-
tors such as eculizumab seem attractive for 
the treatment of aHUS. 12,13 Nevertheless, 
clinical experience with this therapeutic 
modality is quite limited for aHUS, and 
serious questions remain unanswered. It is 
hoped that with further elucidation of the 
molecular mechanisms, better measures 
will become available in the near future to 
tackle the serious business of aHUS. 
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 During hypoxic challenges, the reduced 
availability of oxygen triggers an increase 
in erythropoiesis of the organism, which 
results in an augmented oxygen-carrying 
capacity. In mammalians, this response to 
hypoxic stimuli is mediated by the eryth-
ropoiesis-stimulating hormone erythro-
poietin (EPO). With the exception of a 
few hepatic EPO-producing cells, the bulk 
of systemic EPO in adult mammals is gen-
erated in the renal cortex. 1,2 
 Increased production of EPO in 
response to hypoxic stimuli is virtually 
entirely due to enhanced transcriptional 
activity of the  EPO gene. Th e functional 
linkage between changes in tissue oxygen 
tension and altered EPO transcription 
is provided by the hypoxia-inducible 
transcription factors (HIFs). 
 HIF is a heterodimeric protein consist-
ing of an   - and a   -subunit. Th ree diff er-
ent   -subunits of HIF have been described 
(HIF-1  , HIF-2  , and HIF-3  ). Th e vari-
ous HIF  subunits are regulated by oxy-
gen tension at the protein level, whereas 
the   -subunit is constitutively expressed. 
In normoxia, HIF  is continuously syn-
thesized; however, steady-state levels in 
the cells are low, as HIF  is rapidly 
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 Functional evidence confirmed 
by histological localization: 
overlapping expression 
of erythropoietin and HIF-2  
in interstitial fibroblasts 
of the renal cortex 
 Hayo  Castrop 1 and  Armin  Kurtz 1 
 Erythropoietin (EPO) is the central hormone in the regulation of 
erythropoiesis. Synthesis of EPO and its constitutive release into the 
circulation are controlled by the transcriptional activity of the  EPO gene. 
A key regulator of  EPO is the dimeric hypoxia-inducible transcription factor 
(HIF), which has three isoforms. Paliege and co-workers provide convincing 
morphological evidence that it is the HIF-2 isoform that essentially triggers 
 EPO in the kidney, which is the primary source of EPO in the body. 
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 ubiquitinated and targeted to proteasomal 
degradation. Th is degradation of HIF  is 
mediated by the interaction of HIF  with 
the tumor suppressor von Hippel – Lindau 
protein (pVHL), which specifi cally inter-
acts with hydroxylated HIF  . Hydroxyla-
tion of HIF  , in turn, depends on the 
presence of oxygen as a substrate for HIF 
prolyl-hydroxylases. In hypoxia, the inter-
action between HIF  and pVHL is sup-
pressed because of reduced HIF 
hydroxylation; consequently, HIF  accu-
mulates in the cell, interacts with the con-
stitut ively expressed    -subunit , 
translocates to the cell nucleus, and even-
tually binds to hypoxia-responsive ele-
ments in target gene promoters. 3  EPO is by 
far not the only HIF-dependent gene; in 
fact, more than 150 genes are known to 
possess functionally relevant hypoxia-
responsive elements in their promoters. 4 
 So, what is the reason for the evolution 
of diff erent types of HIF  subunits? In view 
of the large array of HIF target genes, it 
appears reasonable to assume that diff erent 
HIF  subunits may allow the regulation of 
oxygen-dependent genes in a locally 
defi ned manner. Th us, HIF  expression 
follows distinct cell- and tissue-specifi c 
patterns; HIF-1  is rather ubiquitously 
expressed, whereas HIF-2  expression is 
more restricted to the endothelium of 
blood vessels and distinct cells of the 
kidney, brain, heart, lung, liver, pancreas, 
and intestine. 5 Compared with HIF-1  and 
HIF-2  , relatively few data are available 
regarding the biological function and exact 
localization of HIF-3  . 
 Both HIF-1  and HIF-2  are expressed 
in the kidney and, in principle, may 
account for hypoxia-induced EPO expres-
sion. Although there are data to support 
a role of both HIF  subunits in the regu-
lation of EPO expression  in vitro , there is 
now compelling evidence that — at least 
in the adult organism — HIF-2  is the 
crucial factor driving EPO transcription 
 in vivo . 6,7 Since classical knockout models 
of either HIF-1  or HIF-2  are not viable, 8 
an elegant mouse model with inducible 
inactivation of HIF  was developed. In this 
mouse strain, acute HIF-2  deletion was 
obtained in adult mice by inducible gene 
targeting using the tamoxifen-Cre system. 7 
Acute loss of HIF-2  resulted in anemia in 
tamoxifen-treated transgenic mice. Fur-
thermore, activation of EPO transcription 
during hypoxia was substantially reduced 
in HIF-2  conditional knockout mice, 
whereas conditional deletion of HIF-1  
was essentially without eff ect on the induc-
tion of EPO under hypoxia. 7 Th ese data 
were further confi rmed by evaluation of 
HIF-2  -defi cient mice, which turned out 
to survive at a low percentage when back-
crossed into a specific genetic back-
ground. 9 HIF-2    −  /  −   mice were anemic 
and showed markedly reduced renal EPO 
expression. 9 In summary, the mentioned 
studies, accompanied by convincing 
 in vitro evidence, strongly indicate that 
HIF-2  rather than HIF-1  is relevant for 
the control of renal EPO expression. 
 A functional relevance of HIF-2  for 
the direct control of renal EPO expression 
of course requires that the transcription 
factor component HIF-2  is actually 
present in EPO-expressing cells. Renal 
EPO expression has been shown for a sub-
set of renal cortical interstitial cells, which 
coexpress ecto-5  -nucleotidase. 10 Similar, 
HIF-2  was shown to be expressed in 
renal cortical interstitial cells, although 
the exact nature of these cells and the 
question of a possible coexpression of 
HIF-2  in EPO-producing cells remained 
unsettled. Conversely to HIF-2  , HIF-1  
was detected predominantly in the tubular 
system. 11 Th us, the remaining piece of the 
puzzle still was to be added: the unam-
biguous demonstration of a coexpression 
of HIF-2  and EPO mRNA in the same 
renal cortical interstitial cell type. 
 Th e study by Paliege  et al. 12 (this issue) 
now offers new anatomical insights 
regarding the distribution of HIF-1  , 
HIF-2  , and EPO in the rat kidney. It 
essentially confi rms the functional data, 
which had suggested a key role for HIF-2  
(and not HIF-1  ) in the control of EPO 
expression in the kidney. In line with 
being highly hypoxia-inducible proteins, 
HIF-1  , HIF-2  , and EPO were virtually 
undetectable under normoxic conditions. 
Th en, two experimental maneuvers were 
used to mimic hypoxic conditions: rats 
were either kept under isobaric hypoxia 
(8 % O 2 for 6 hours) or treated with the 
prolyl-hydroxylase inhibitor FG-4497. For 
the two maneuvers, the results were essen-
tially identical: EPO expression was 
induced under  ‘ hypoxic ’ conditions in 
interstitial cells of the renal cortex with a 
higher density of EPO-positive cells in 
deeper than in more superfi cial portions 
of the cortex. Whether this heterogeneous 
 Figure 1  |  HIF - expression in the rat renal cortex under hypoxic conditions. 12  HIF-1 expression 
was restricted to the tubular system. HIF-2 was found in interstitial  fibroblasts and in endothelial 
and glomerular cells. HIF-2 expression overlapped with EPO expression in ecto-5’ -nucleotidase/
CD73-positive interstitial fibroblasts. Interstitial MHC-II-positive cells (dendritic cells, macrophages) 
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distribution within the renal cortex 
refl ects some gradient of oxygen tension 
was not addressed by Paliege  et al. 12 but 
it may appear unlikely, since protein levels 
of HIF-2  were similar in all portions of 
the renal cortex. Th us, HIF-2  was found 
predominantly in interstitial cells of the 
renal cortex. In addition, HIF-2  was 
detected in some scattered endothelial 
and glomerular cells. As the key fi nding, 
there was a marked overlap of EPO- and 
HIF-2  -positive cells: between 83 and 
91 % of EPO-producing interstitial cells 
also stained positive for HIF-2  ; the 
degree of coexpression was slightly higher 
in the deeper than in the more superfi cial 
cortex. Th us, although the vast majority of 
EPO-positive cells also expressed HIF-2  , 
there was apparently a subset of EPO-
expressing cells that did not stain for HIF-2  . 
Whether this fi nding was based on a sen-
sitivity issue of HIF-2  detection or may 
indicate that EPO-producing cells consist 
of two sub-populations — the larger one 
being HIF-2  -dependent and the smaller 
one being HIF-2  -independent — was not 
addressed by Paliege  et al. 12 
 Conversely to HIF-2  , HIF-1  was 
detected in epithelial cells, and there was 
no colocalization with EPO-expressing 
interstitial cells. Th us, the fi ndings of this 
localization study confi rm previous func-
tional evidence indicating that HIF-2  is 
the major factor in oxygen-dependent EPO 
expression. Although the absence of HIF-
1  from EPO-expressing cells of the renal 
cortex excludes a functional relevance of 
HIF-1  for a direct control of EPO tran-
scription, HIF-1  is well able to drive EPO 
expression in extrarenal tissues. 13,14 
 Paliege  et al. 12 furthermore attempted to 
characterize the nature of HIF-2  - and 
EPO-coexpressing interstitial cells. As a 
marker for interstitial fi broblasts of the 
renal cortex, they used ecto-5  -nucleoti-
dase. 10 Most HIF-2  - and EPO-positive 
cells also stained for ecto-5  -nucleotidase, 
whereas no coexpression with the den-
dritic-cell marker major histocompatibility 
complex II was detected, suggesting — but 
not proving — that the oxygen-sensitive 
interstitial cells of the renal cortex mainly 
represent fi broblasts ( Figure 1 ). 
 In summary, the convincing localiza-
tion study by Paliege  et al. 12 now adds the 
last piece to the puzzle and provides a 
 convincing — anatomical — basis for what 
we had expected from functional studies: 
HIF-2  is an indispensible prerequisite for 
oxygen-dependent EPO expression in the 
adult kidney. 
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 KDIGO guideline for the care 
of kidney transplant recipients 
will be resource challenged 
 Francis L.  Delmonico 1 
 The Executive Summary of the KDIGO Clinical Practice Guideline for the 
Care of Kidney Transplant Recipients is presented in this issue of  Kidney 
International .  This guideline will require careful attention for 
implementation in the context of available resources within each 
country, especially those with underdeveloped economies. 
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of Kidney Transplant Recipients is pre-
sented to the international community. 
The complete report, including the 
rationale and references for each recom-
mendation, is to be published in the 
 American Journal of Transplantation 
( AJT ). 2 Th e complete report is also avail-
able on the websites of KDIGO (Kidney 
Disease: Improving Global Outcomes) 
